Signal Peptide Database - Mammalia

 Entry Details
ID   332
Source Database   UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number   P54803    (Created: 1996-10-01 Updated: 2009-01-20)
UniProtKB/Swiss-Prot Entry Name   GALC_HUMAN
Protein Name   Galactocerebrosidase
Gene   GALC
Organism Scientific   Homo sapiens
Organism Common   Human
Lineage   Eukaryota
  Metazoa
    Chordata
      Craniata
        Vertebrata
          Euteleostomi
            Mammalia
              Eutheria
                Euarchontoglires
                  Primates
                    Haplorrhini
                      Catarrhini
                        Hominidae
                          Homo
Protein Length [aa]   669
Protein Mass [Da]   75147
Features  
TypeDescriptionStatusStartEnd
signal peptide         1   26
chain   Galactocerebrosidase      27   669
glycosylation site   N-linked (GlcNAc...)   potential   127   127
glycosylation site   N-linked (GlcNAc...)   potential   363   363
glycosylation site   N-linked (GlcNAc...)   potential   387   387
glycosylation site   N-linked (GlcNAc...)   potential   540   540
glycosylation site   N-linked (GlcNAc...)   potential   543   543
glycosylation site   N-linked (GlcNAc...)   potential   586   586
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; bilateral cherry red spots)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD; Arab patients)      0   0
sequence variant   (in GLD; loss of activity)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD; adult)      0   0
sequence variant   (in significant reduction of activity when associated with T-546; dbSNP:rs421262)      0   0
sequence variant   (in GLD; adult)      0   0
sequence variant   (in GLD; infantile; Druze patients)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; belgian patient)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in common polymorphism; dbSNP:rs398607)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in dbSNP:rs1805079)      0   0
sequence variant   (in GLD; adult)      0   0
sequence variant   (in GLD; adult)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; adult; reduction of activity; when associated with V-289)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in dbSNP:rs1805078)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; infantile; significant reduction of activity)      0   0
sequence variant   (in GLD)      0   0
sequence variant   (in GLD; late infantile)      0   0
sequence variant         0   0
splice variant   (in isoform 2)      0   0
splice variant   (in isoform 2)      392   669
SP Length   26
 ----+----1----+----2----+----3----+----4----+----5
Signal Peptide MTAAAGSAGRAAVPLLLCALLAPGGA
Sequence MTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGAVSGGGA
TSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSH
MHYALDENYFRGYEWWLMKEAKKRNP
NITLIGLPWSFPGWLGKGFDWPYV
NLQLTAYYVVTWIVGAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQ
GLQRVKIIASDNLWESISASMLLDAELFKVVDVIGAHYPGTHSAKDAKLT
GKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGYMTSTIAWNLVASYYEQ
LPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWYYLKTVGHLEK
GGSYVALTDGLG
NLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGS
FSEIPELQVWYTKLGKTSERFLFKQLDSLWLLDSDGSFTLSLHEDELFTL
TTLTTGRKGSYPLPPKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEY
FTNIEDPGEHHFTLRQVLNQRPITWAADASNTISIIGDYNWTNLTIKCDV
YIETPDTGGVFIAGRVNKGGILIRSARGIFFWIFANGSYRVTGDLAGWII
YALGRVEVTAKKWYTLTLTIKGHFASGMLNDKSLWTDIPVNFPKNGWAAI
GTHSFEFAQFDNFLVEATR
Original MTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGAVSGGGA
TSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSH
MHYALDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFDWPYV
NLQLTAYYVVTWIVGAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQ
GLQRVKIIASDNLWESISASMLLDAELFKVVDVIGAHYPGTHSAKDAKLT
GKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGYMTSTIAWNLVASYYEQ
LPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWYYLKTVGHLEK
GGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGS
FSEIPELQVWYTKLGKTSERFLFKQLDSLWLLDSDGSFTLSLHEDELFTL
TTLTTGRKGSYPLPPKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEY
FTNIEDPGEHHFTLRQVLNQRPITWAADASNTISIIGDYNWTNLTIKCDV
YIETPDTGGVFIAGRVNKGGILIRSARGIFFWIFANGSYRVTGDLAGWII
YALGRVEVTAKKWYTLTLTIKGHFASGMLNDKSLWTDIPVNFPKNGWAAI
GTHSFEFAQFDNFLVEATR
 ----+----1----+----2----+----3----+----4----+----5
Hydropathies  
 

© 2007-2017 Dr. Katja Kapp, Kassel & thpr.net e. K., Dresden, Germany, last update 2010-06-11